Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus (NASDAQ: TEM) announced eight abstracts accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium (Jan 8–10, San Francisco). Using Tempus Lens on de-identified clinical, genomic, and transcriptomic data, the studies report: subtype-specific DNA alterations in appendiceal neoplasms; CLDN1 expression linked to immune infiltration and improved survival with 1L chemo+IO in advanced biliary tract cancers; molecular/immune differences by age in enteropancreatic NETs; trends toward better survival with platinum in pancreatic cancers with non-BRCA/PALB2 DDR mutations (median rwOS 11.7 vs 9.8 months, p=0.471); PIN1 expression associations in PDAC; KRAS status and co-alteration profiles in resected pancreatic cancer; RAD51/GATA6 transcriptomic signatures predicting platinum benefit in BRCA/PALB2 wild-type mPC; and RTK amplifications present in ~10% of GI cancers with immunosuppressive TME features.
Tempus (NASDAQ:TEM) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026. Founder and CEO Eric Lefkofsky will deliver a presentation and live Q&A on January 12, 2026, 1:30–2:10 PM PST.
The presentation will be available via live webcast at the conference portal.
Tempus (NASDAQ: TEM) announced ten abstracts accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (Dec 9–12). The posters span multimodal AI analyses integrating genomic, transcriptomic, and real-world clinical data to refine risk stratification, characterize ESR1 and PIK3CA co-mutations (n=8,626), profile tumor immune microenvironments across subtypes and metastatic sites, assess biomarkers for trastuzumab deruxtecan response, and evaluate treatment sequencing and real-world outcomes in HR+/HER2- metastatic breast cancer.
Presentations highlight potential biomarkers, racial and male breast cancer insights, and implications for patient selection and therapy optimization.
Tempus (NASDAQ:TEM) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 in New York City. Jim Rogers, Chief Financial Officer, will join a fireside chat at 10:30 AM ET. A live webcast will be available via the company’s Investor Relations events page.
Tempus (NASDAQ: TEM) launched a multi-year research study in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI) to build a comprehensive, multi-omic dataset for follicular lymphoma (FL).
The study will enroll FL patients and apply next-generation sequencing, proteomics, and methylation analysis to integrate molecular profiling with real-world clinical data. The collaboration is Tempus’ first study partnership with a nonprofit foundation and aims to support biomarker discovery, whole-genome sequencing validation, and precision-medicine research.
FL represents roughly 10–20% of U.S. non-Hodgkin lymphoma cases; the release notes ~20% of patients progress within two years after chemoimmunotherapy and a 50% five-year overall survival, underscoring research needs.
Tempus (NASDAQ: TEM) announced six abstracts accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025, held November 5–9 in National Harbor, Maryland.
Key research includes: a multi-omic Immune Profile Score (IPS) predicting ICI outcomes in rare advanced solid cancers (n=90) and MSS colorectal cancer (n=46); a MAIT cell prevalence analysis across 190,189 patients; an automated TargetR multi-omics framework; an ultrahigh TMB ≥40 mut/MB analysis in 17,449 patients showing improved real-world response and survival; and AR alteration effects in 1,556 castration-resistant prostate cancer patients.
Summary not available.
Tempus (NASDAQ:TEM) will participate in the Stifel 2025 Healthcare Conference in New York City on Thursday, November 13, 2025. Jim Rogers, Tempus chief financial officer, will appear in a fireside chat at 10:00 AM ET. A live webcast will be available via the company’s investor relations events page or the provided webcast link for remote viewers.
Tempus (NASDAQ:TEM) will report third-quarter 2025 financial results on November 4, 2025.
The company will hold its earnings conference call at 4:30 PM ET featuring Founder and CEO Eric Lefkofsky and CFO Jim Rogers. A live audio webcast will be available on Tempus’ Investor Relations events page. Call access details: Conference ID 5436492; USA & Canada toll-free (800) 715-9871; U.S. toll (646) 307-1963. Live webcast link provided for listeners.
Ambry Genetics (NASDAQ: TEM) announced publication on October 20, 2025 of a 10-year peer-reviewed study in Genetics in Medicine analyzing exome reanalysis across racial, ethnic, and ancestral groups.
The study found lower rates of provider-initiated exome reanalysis for Hispanic and Latino (22%), Asian (21%), and African American and Black (17%) patients versus White patients (25%). Reanalysis increased positive results across all groups. Ambry's Patient for Life™ program provides ongoing laboratory-driven reanalysis without a provider request, removing the provider-referral barrier and aiming to improve equity in access to updated genetic findings.